Meeting
2019 ASCO Annual Meeting
Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).
Authors
Paul G. Richardson
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Paul G. Richardson , Sundar Jagannath , Ajai Chari , Dan T. Vogl , Meletios A. Dimopoulos , Philippe Moreau , David Dingli , L J Wei , Lingling Li , Shijie Tang , William Reichman , Michael G. Kauffman , Jatin J. Shah , Sharon Shacham , Sagar Lonial
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT02336815
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8014)
DOI
10.1200/JCO.2019.37.15_suppl.8014
Abstract #
8014
Poster Bd #
340
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto
Poster
2020 ASCO Virtual Scientific Program
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
First Author: Cristina Gasparetto
Poster
2018 ASCO Annual Meeting
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew Jenho Yee
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee